向小鼠眼睛注射眼部药物植入物的方案。
A protocol to inject ocular drug implants into mouse eyes.
机构信息
Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, CA 94304, USA.
Molecular Surgery Laboratory, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, CA 94304, USA.
出版信息
STAR Protoc. 2022 Jan 29;3(1):101143. doi: 10.1016/j.xpro.2022.101143. eCollection 2022 Mar 18.
Ocular drug implants (ODIs) are beneficial for treating ocular diseases. However, the lack of a robust injection approach for small-eyed model organisms has been a major technical limitation in developing ODIs. Here, we present a cost-effective, minimally invasive protocol to deliver ODIs into the mouse vitreous called Mouse Implant Intravitreal Injection (MI3). MI3 provides two alternative surgical approaches (air-pressure or plunger) to deliver micro-scaled ODIs into milli-scaled eyes, and expands the preclinical platforms to determine ODIs' efficacy, toxicity, and pharmacokinetics. For complete details on the use and execution of this protocol, please refer to Sun et al. (2021).
眼内药物植入物 (Ocular Drug Implants, ODIs) 对于治疗眼部疾病非常有益。然而，在开发 ODIs 时，缺乏一种用于小眼球模式生物的稳健注射方法一直是一个主要的技术限制。在这里，我们提出了一种具有成本效益、微创的方法来将 ODIs 递送到小鼠玻璃体中，称为 Mouse Implant Intravitreal Injection (MI3)。MI3 提供了两种替代的手术方法（气压或柱塞），将微尺度的 ODIs 递送到毫尺度的眼睛中，并扩展了临床前平台，以确定 ODIs 的疗效、毒性和药代动力学。有关该方案使用和执行的完整详细信息，请参见 Sun 等人 (2021)。
Zotero 插件